Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, ...

You’ve probably heard the stories: For every man who has cut carbs from his diet and dropped 10 pounds, there’s a woman who’s done exactly the same thing and lost 2. Research backs up this frustrating ...

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors, citing ...

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual agreement." ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...